COMPANY PROFILE

Kiniksa Pharmaceuticals

Explore full profile

Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions

Lexington, United StatesFounded 2015Biotech & Life Sciences

Valuation $5.41B Market cap · 2026

Revenue $994M Latest reported FY

EBITDA $180M Latest reported FY

Total funding $100–500M Disclosed equity funding

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and delivering therapies for patients with debilitating diseases and unmet medical needs. The company operates in the healthcare and pharmaceutical market, targeting conditions that have limited treatment options. Kiniksa's business model revolves around research and development (R&D) of novel therapies, clinical trials, and subsequent commercialization of approved drugs. Revenue is generated through the sale of these therapies, partnerships, and potential licensing agreements. The company serves patients, healthcare providers, and medical institutions, aiming to improve patient outcomes and quality of life. Kiniksa's approach is patient-centric, emphasizing urgency and integrity in its operations.

Source: Dealroom company data

At a glance

Founded: 2015
Headquarters: Lexington, United States
Listing: IPO 2018
Sector: Biotech & Life Sciences
Power Law: Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

SOSTRS Ohio

Talent

Book a demo to see the people

Team profiled 19 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

4 countries with
team presence

🇺🇸 United States95.8%

🇬🇧 United Kingdom1.9%

🇨🇭 Switzerland1.3%

🇳🇱 Netherlands0.7%

4 countries shown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States80.9%

🇮🇳 India12.7%

🇮🇹 Italy3.6%

🇪🇬 Egypt1.8%

🇬🇧 United Kingdom0.9%

Top 5 markets shown

Patents

Estimated portfolio value

$24M

14 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kiniksa Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kiniksa Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles